Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151


miR-335 inhibits small cell lung cancer bone metastases via IGF-IR and RANKL pathways.

Gong M, Ma J, Guillemette R, Zhou M, Yang Y, Yang Y, Hock JM, Yu X.

Mol Cancer Res. 2014 Jan;12(1):101-10. doi: 10.1158/1541-7786.MCR-13-0136. Epub 2013 Aug 21.


MGr1-Ag promotes invasion and bone metastasis of small-cell lung cancer in vitro and in vivo.

Zhang F, Wang Y, Xu M, Dong H, Liu N, Zhou J, Pang H, Ma N, Zhang N, Pei Y, Zhang H, Liu L.

Oncol Rep. 2013 Jun;29(6):2283-90. doi: 10.3892/or.2013.2396. Epub 2013 Apr 9.


Downregulation of CXCR4 by SDF-KDEL in SBC-5 cells inhibits their migration in vitro and organ metastasis in vivo.

Ma N, Pang H, Shen W, Zhang F, Cui Z, Wang J, Wang J, Liu L, Zhang H.

Int J Mol Med. 2015 Feb;35(2):425-32. doi: 10.3892/ijmm.2014.2033. Epub 2014 Dec 10.


RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.

Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC.

Prostate. 2008 Jan 1;68(1):92-104.


The Biological Effects of Dickkopf1 on Small Cell Lung Cancer Cells and Bone Metastasis.

Pang H, Ma N, Jiao M, Shen W, Xin B, Wang T, Zhang F, Liu L, Zhang H.

Oncol Res. 2017 Jan 2;25(1):35-42. doi: 10.3727/096504016X14719078133249.


The effect of down regulation of calcineurin Aα by lentiviral vector-mediated RNAi on the biological behavior of small-cell lung cancer and its bone metastasis.

Ma NQ, Liu LL, Min J, Wang JW, Jiang WF, Liu Y, Feng YG, Su HC, Feng YM, Zhang HL.

Clin Exp Metastasis. 2011 Dec;28(8):765-78. doi: 10.1007/s10585-011-9408-6. Epub 2011 Jul 23.


miR-140 suppresses tumor growth and metastasis of non-small cell lung cancer by targeting insulin-like growth factor 1 receptor.

Yuan Y, Shen Y, Xue L, Fan H.

PLoS One. 2013 Sep 10;8(9):e73604. doi: 10.1371/journal.pone.0073604. eCollection 2013.


DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer.

Cao J, Song Y, Bi N, Shen J, Liu W, Fan J, Sun G, Tong T, He J, Shi Y, Zhang X, Lu N, He Y, Zhang H, Ma K, Luo X, Lv L, Deng H, Cheng J, Zhu J, Wang L, Zhan Q.

Cancer Res. 2013 Jun 1;73(11):3326-35. doi: 10.1158/0008-5472.CAN-12-3055. Epub 2013 Apr 16.


Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer.

Tanaka N, Toyooka S, Soh J, Kubo T, Yamamoto H, Maki Y, Muraoka T, Shien K, Furukawa M, Ueno T, Asano H, Tsukuda K, Aoe K, Miyoshi S.

Lung Cancer. 2012 Apr;76(1):32-8. doi: 10.1016/j.lungcan.2011.10.002. Epub 2011 Nov 1.


Down-regulation of β3-integrin inhibits bone metastasis of small cell lung cancer.

Li N, Zhang JP, Guo S, Min J, Liu LL, Su HC, Feng YM, Zhang HL.

Mol Biol Rep. 2012 Mar;39(3):3029-35. doi: 10.1007/s11033-011-1065-y. Epub 2011 Jun 16.


Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and invasion of small-cell lung cancer (SCLC) cells.

Wang ZX, Lu BB, Yang JS, Wang KM, De W.

J Surg Res. 2011 Nov;171(1):127-35. doi: 10.1016/j.jss.2009.12.016. Epub 2010 Jan 14.


MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein.

Kuo PL, Liao SH, Hung JY, Huang MS, Hsu YL.

Biochim Biophys Acta. 2013 Jun;1830(6):3756-66. doi: 10.1016/j.bbagen.2013.02.022. Epub 2013 Mar 1.


Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.

Holland PM, Miller R, Jones J, Douangpanya H, Piasecki J, Roudier M, Dougall WC.

Cancer Biol Ther. 2010 Apr 1;9(7):539-50. Epub 2010 Apr 1.


RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.

Miller RE, Jones JC, Tometsko M, Blake ML, Dougall WC.

J Thorac Oncol. 2014 Mar;9(3):345-54. doi: 10.1097/JTO.0000000000000070.


Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.

Peng X, Guo W, Ren T, Lou Z, Lu X, Zhang S, Lu Q, Sun Y.

PLoS One. 2013;8(3):e58361. doi: 10.1371/journal.pone.0058361. Epub 2013 Mar 13.


Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.

Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, Chen Y, Deng G, Tanaka Y, Dahiya R.

Clin Cancer Res. 2011 Aug 15;17(16):5287-98. doi: 10.1158/1078-0432.CCR-10-2619. Epub 2010 Dec 15.


RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4.

Nakamura ES, Koizumi K, Kobayashi M, Saitoh Y, Arita Y, Nakayama T, Sakurai H, Yoshie O, Saiki I.

Clin Exp Metastasis. 2006;23(1):9-18. Epub 2006 Jul 5.


miR-27a regulates the self renewal of the H446 small cell lung cancer cell line in vitro.

Miao Y, Li J, Qiu X, Li Y, Wang Z, Luan Y.

Oncol Rep. 2013 Jan;29(1):161-8. doi: 10.3892/or.2012.2095. Epub 2012 Oct 19.


Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.

Kurio N, Shimo T, Fukazawa T, Takaoka M, Okui T, Hassan NM, Honami T, Hatakeyama S, Ikeda M, Naomoto Y, Sasaki A.

Exp Cell Res. 2011 May 1;317(8):1134-46. doi: 10.1016/j.yexcr.2011.02.008. Epub 2011 Feb 19.


Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.

Logan JG, Sophocleous A, Marino S, Muir M, Brunton VG, Idris AI.

J Bone Miner Res. 2013 May;28(5):1229-42. doi: 10.1002/jbmr.1847.

Supplemental Content

Support Center